Pasquini, MC, Wang, Z, Horowitz, MM, Gale, RP. Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clinical Transplants. 2010:87–105.Google Scholar

Girmenia, C, Raiola, AM, Piciocchi, A, Algarotti, A, Stanzani, M, Cudillo, L, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(6):872–80.Google ScholarPubMed

De Pauw, B, Walsh, TJ, Donnelly, JP, Stevens, DA, Edwards, JE, Calandra, T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;46(12):1813–21.CrossRefGoogle Scholar

Wingard, JR. Lipid formulations of amphotericins: are you a lumper or a splitter? Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2002;35(7):891–5.CrossRefGoogle ScholarPubMed

Dodds Ashley, ES, Lewis, R, Lewis, JS, Martin, C, Andes, D. Pharmacology of systemic antifungal agents. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2006;43:S28–39.CrossRefGoogle Scholar

Walsh, TJ, Anaissie, EJ, Denning, DW, Herbrecht, R, Kontoyiannis, DP, Marr, KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;46(3):327–60.CrossRefGoogle ScholarPubMed

Maertens, J, Cornely, OA, Ullmann, AJ, Heinz, WJ, Krishna, G, Patino, H, et al. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrobial Agents and Chemotherapy. 2014;58(7):3610–7.CrossRefGoogle ScholarPubMed

Girmenia, C, Barosi, G, Piciocchi, A, Arcese, W, Aversa, F, Bacigalupo, A, et al. Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(8):1080–8.Google ScholarPubMed

Wingard, JR, Merz, WG, Rinaldi, MG, Johnson, TR, Karp, JE, Saral, R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. The New England Journal of Medicine. 1991;325(18):1274–7.CrossRefGoogle ScholarPubMed

Marr, KA, Seidel, K, Slavin, MA, Bowden, RA, Schoch, HG, Flowers, ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96(6):2055–61.CrossRefGoogle ScholarPubMed

Winston, DJ, Maziarz, RT, Chandrasekar, PH, Lazarus, HM, Goldman, M, Blumer, JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Annals of Internal Medicine. 2003;138(9):705–13.CrossRefGoogle Scholar

Marr, KA, Crippa, F, Leisenring, W, Hoyle, M, Boeckh, M, Balajee, SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527–33.CrossRefGoogle ScholarPubMed

Vehreschild, JJ, Sieniawski, M, Reuter, S, Arenz, D, Reichert, D, Maertens, J, et al. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. International Journal of Antimicrobial Agents. 2009;34(5):446–50.CrossRefGoogle ScholarPubMed

Wingard, JR, Carter, SL, Walsh, TJ, Kurtzberg, J, Small, TN, Baden, LR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–8.CrossRefGoogle ScholarPubMed

Marks, DI, Pagliuca, A, Kibbler, CC, Glasmacher, A, Heussel, CP, Kantecki, M, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. British Journal of Haematology. 2011;155(3):318–27.CrossRefGoogle ScholarPubMed

Takagi, S, Araoka, H, Uchida, N, Uchida, Y, Kaji, D, Ota, H, et al. A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning. International Journal of Hematology. 2014;99(5):652–8.Google ScholarPubMed

Cordonnier, C, Rovira, M, Maertens, J, Olavarria, E, Faucher, C, Bilger, K, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95(10):1762–8.CrossRefGoogle ScholarPubMed

Gergis, U, Markey, K, Greene, J, Kharfan-Dabaja, M, Field, T, Wetzstein, G, et al. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GvHD. Bone Marrow Transplantation. 2010;45(4):662–7.CrossRefGoogle ScholarPubMed

Ullmann, AJ, Lipton, JH, Vesole, DH, Chandrasekar, P, Langston, A, Tarantolo, SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. The New England Journal of Medicine. 2007;356(4):335–47.CrossRefGoogle ScholarPubMed

Sanchez-Ortega, I, Patino, B, Arnan, M, Peralta, T, Parody, R, Gudiol, C, et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplantation. 2011;46(5):733–9.CrossRefGoogle ScholarPubMed

Winston, DJ, Bartoni, K, Territo, MC, Schiller, GJ. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2011;17(4):507–15.CrossRefGoogle ScholarPubMed

Chaftari, AM, Hachem, RY, Ramos, E, Kassis, C, Campo, M, Jiang, Y, et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. Transplantation. 2012;94(3):302–8.CrossRefGoogle ScholarPubMed

Hahn, J, Stifel, F, Reichle, A, Holler, E, Andreesen, R. Clinical experience with posaconazole prophylaxis: a retrospective analysis in a haematological unit. Mycoses. 2011;54 (Suppl 1):12–6.CrossRefGoogle Scholar

Chou, LS, Lewis, RE, Ippoliti, C, Champlin, RE, Kontoyiannis, DP. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy. 2007;27(12):1644–50.CrossRefGoogle ScholarPubMed

de Fabritiis, P, Spagnoli, A, Di Bartolomeo, P, Locasciulli, A, Cudillo, L, Milone, G, et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplantation. 2007;40(3):245–9.CrossRefGoogle ScholarPubMed

van Burik, JA, Ratanatharathorn, V, Stepan, DE, Miller, CB, Lipton, JH, Vesole, DH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2004;39(10):1407–16.CrossRefGoogle ScholarPubMed

Huang, X, Chen, H, Han, M, Zou, P, Wu, D, Lai, Y, et al. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2012;18(10):1509–16.CrossRefGoogle ScholarPubMed

Ziakas, PD, Kourbeti, IS, Mylonakis, E. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis. Clinical Therapeutics. 2014;36(2):292–306 e1.CrossRefGoogle ScholarPubMed

Jansen, J, Akard, LP, Wack, MF, Thompson, JM, Dugan, MJ, Leslie, JK, et al. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation. Mycoses. 2006;49(5):397–404.CrossRefGoogle ScholarPubMed

Cordonnier, C, Mohty, M, Faucher, C, Pautas, C, Robin, M, Vey, N, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. International Journal of Antimicrobial Agents. 2008;31(2):135–41.CrossRefGoogle ScholarPubMed

Penack, O, Schwartz, S, Martus, P, Reinwald, M, Schmidt-Hieber, M, Thiel, E, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2006;17(8):1306–12.CrossRefGoogle ScholarPubMed

Rijnders, BJ, Cornelissen, JJ, Slobbe, L, Becker, MJ, Doorduijn, JK, Hop, WC, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;46(9):1401–8.CrossRefGoogle ScholarPubMed

Walsh, TJ, Finberg, RW, Arndt, C, Hiemenz, J, Schwartz, C, Bodensteiner, D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. The New England Journal of Medicine. 1999;340(10):764–71.CrossRefGoogle ScholarPubMed

Wingard, JR, White, MH, Anaissie, E, Raffalli, J, Goodman, J, Arrieta, A, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2000;31(5):1155–63.CrossRefGoogle ScholarPubMed

Walsh, TJ, Pappas, P, Winston, DJ, Lazarus, HM, Petersen, F, Raffalli, J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. The New England Journal of Medicine. 2002;346(4):225–34.CrossRefGoogle ScholarPubMed

Walsh, TJ, Teppler, H, Donowitz, GR, Maertens, JA, Baden, LR, Dmoszynska, A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. The New England Journal of Medicine. 2004;351(14):1391–402.CrossRefGoogle ScholarPubMed

Kubiak, DW, Bryar, JM, McDonnell, AM, Delgado-Flores, JO, Mui, E, Baden, LR, et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clinical Therapeutics. 2010;32(4):637–48.CrossRefGoogle ScholarPubMed

Yamaguchi, M, Kurokawa, T, Ishiyama, K, Aoki, G, Ueda, M, Matano, S, et al. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study. Annals of Hematology. 2011;90(10):1209–17.CrossRefGoogle ScholarPubMed

Chen, SC, Slavin, MA, Sorrell, TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;71(1):11–41.CrossRefGoogle ScholarPubMed

Anaissie, EJ, Vartivarian, SE, Abi-Said, D, Uzun, O, Pinczowski, H, Kontoyiannis, DP, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. The American Journal of Medicine. 1996;101(2):170–6.CrossRefGoogle ScholarPubMed

Mora-Duarte, J, Betts, R, Rotstein, C, Colombo, AL, Thompson-Moya, L, Smietana, J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. The New England Journal of Medicine. 2002;347(25):2020–9.CrossRefGoogle ScholarPubMed

Ullmann, AJ, Akova, M, Herbrecht, R, Viscoli, C, Arendrup, MC, Arikan-Akdagli, S, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2012;18 (Suppl 7):53–67.CrossRefGoogle ScholarPubMed

Pappas, PG, Rotstein, CM, Betts, RF, Nucci, M, Talwar, D, De Waele, JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2007;45(7):883–93.CrossRefGoogle ScholarPubMed

Kuse, ER, Chetchotisakd, P, da Cunha, CA, Ruhnke, M, Barrios, C, Raghunadharao, D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369(9572):1519–27.CrossRefGoogle ScholarPubMed

Ostrosky-Zeichner, L, Oude Lashof, AM, Kullberg, BJ, Rex, JH. Voriconazole salvage treatment of invasive candidiasis. European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology. 2003;22(11):651–5.CrossRefGoogle ScholarPubMed

Kullberg, BJ, Sobel, JD, Ruhnke, M, Pappas, PG, Viscoli, C, Rex, JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005;366(9495):1435–42.CrossRefGoogle ScholarPubMed

Herbrecht, R, Denning, DW, Patterson, TF, Bennett, JE, Greene, RE, Oestmann, JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. The New England Journal of Medicine. 2002;347(6):408–15.CrossRefGoogle ScholarPubMed

Bowden, R, Chandrasekar, P, White, MH, Li, X, Pietrelli, L, Gurwith, M, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2002;35(4):359–66.CrossRefGoogle ScholarPubMed

Walsh, TJ, Raad, I, Patterson, TF, Chandrasekar, P, Donowitz, GR, Graybill, R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2007;44(1):2–12.CrossRefGoogle ScholarPubMed

Heinz, WJ, Grau, A, Ulrich, A, Helle-Beyersdorf, A, Zirkel, J, Schirmer, D, et al. Impact of benzodiazepines on posaconazole serum concentrations: a population-based pharmacokinetic study on drug interaction. Current Medical Research and Opinion. 2012;28(4):551–7.CrossRefGoogle Scholar

Jang, SH, Colangelo, PM, Gobburu, JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clinical Pharmacology and Therapeutics. 2010;88(1):115–9.CrossRefGoogle ScholarPubMed

Andes, D, Pascual, A, Marchetti, O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrobial Agents and Chemotherapy. 2009;53(1):24–34.CrossRefGoogle ScholarPubMed

Heinz, WJ, Einsele, H, Helle-Beyersdorf, A, Zirkel, J, Grau, A, Schirmer, D, et al. Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease: An Official Journal of the Transplantation Society. 2013;15(5):449–56.CrossRefGoogle ScholarPubMed

Lebeaux, D, Lanternier, F, Elie, C, Suarez, F, Buzyn, A, Viard, JP, et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrobial Agents and Chemotherapy. 2009;53(12):5224–9.CrossRefGoogle ScholarPubMed

Cornely, OA, Helfgott, D, Langston, A, Heinz, W, Vehreschild, JJ, Vehreschild, MJ, et al. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrobial Agents and Chemotherapy. 2012;56(5):2652–8.CrossRefGoogle ScholarPubMed

Denning, DW, Ribaud, P, Milpied, N, Caillot, D, Herbrecht, R, Thiel, E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2002;34(5):563–71.CrossRefGoogle ScholarPubMed

Pascual, A, Calandra, T, Bolay, S, Buclin, T, Bille, J, Marchetti, O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;46(2):201–11.CrossRefGoogle ScholarPubMed

Park, WB, Kim, NH, Kim, KH, Lee, SH, Nam, WS, Yoon, SH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2012;55(8):1080–7.CrossRefGoogle ScholarPubMed

Ueda, K, Nannya, Y, Kumano, K, Hangaishi, A, Takahashi, T, Imai, Y, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. International Journal of Hematology. 2009;89(5):592–9.CrossRefGoogle ScholarPubMed

Troke, PF, Hockey, HP, Hope, WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrobial Agents and Chemotherapy. 2011;55(10):4782–8.CrossRefGoogle ScholarPubMed

Maertens, J, Glasmacher, A, Herbrecht, R, Thiebaut, A, Cordonnier, C, Segal, BH, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer. 2006;107(12):2888–97.CrossRefGoogle ScholarPubMed

Kontoyiannis, DP, Ratanatharathorn, V, Young, JA, Raymond, J, Laverdiere, M, Denning, DW, et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transplant Infectious Disease: An Official Journal of the Transplantation Society. 2009;11(1):89–93.CrossRefGoogle ScholarPubMed

Meletiadis, J, Petraitis, V, Petraitiene, R, Lin, P, Stergiopoulou, T, Kelaher, AM, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in-vitro and in vivo correlation. The Journal of Infectious Diseases. 2006;194(7):1008–18.CrossRefGoogle ScholarPubMed

Marr, KA, Schlamm, H, Rottinghaus, ST,Jagannatha, S, Bow, EJ, Wingard, JR, et al. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March–April, 2012.Google Scholar

Reed, C, Bryant, R, Ibrahim, AS, Edwards, J Jr., Filler, SG, Goldberg, R, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;47(3):364–71.CrossRefGoogle ScholarPubMed

Cunha, C, Aversa, F, Lacerda, JF, Busca, A, Kurzai, O, Grube, M, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. The New England Journal of Medicine. 2014;370(5):421–32.CrossRefGoogle ScholarPubMed

Bochud, PY, Chien, JW, Marr, KA, Leisenring, WM, Upton, A, Janer, M, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. The New England Journal of Medicine. 2008;359(17):1766–77.CrossRefGoogle ScholarPubMed